Open AccessPhase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Author(s) -
Benjamin Watkins,
Muna Qayed,
Courtney McCracken,
Brandi Bratrude,
Kayla Betz,
Yvonne Suessmuth,
Alison Yu,
Shauna Sinclair,
Scott N. Furlan,
Steven E. Bosinger,
Victor Tkachev,
James Rhodes,
Audrey G. Tumlin,
Alexandria Narayan,
Kayla Cribbin,
Scott Gillespie,
Ted Gooley,
Marcelo C. Pasquini,
Kyle Hebert,
Urvi Kapoor,
André Rogatko,
Mourad Tighiouart,
Sungjin Kim,
Catherine Bresee,
Sung Won Choi,
Jeffrey E. Davis,
Christine N. Duncan,
Roger Giller,
Michael Grimley,
Andrew C. Harris,
David A. Jacobsohn,
Nahal Lalefar,
Maxim Norkin,
Nosha Farhadfar,
Michael A. Pulsipher,
Shalini Shenoy,
Aleksandra Petrović,
Kirk R. Schultz,
Gregory A. Yanik,
Edmund K. Waller,
John E. Levine,
James L.M. Ferrara,
Bruce R. Blazar,
Amelia Langston,
John Horan,
Leslie S. Kean
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.01086
Subject(s) - abatacept , medicine , hazard ratio , clinical endpoint , placebo , calcineurin , methotrexate , transplantation , gastroenterology , immunology , clinical trial , confidence interval , rituximab , alternative medicine , pathology , lymphoma
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD.